Inclusion Criteria

• Persistent generalized lymphadenopathy (PGL) (CDC-Group III), defined as palpable lymphadenopathy (nodes of 1 cm or greater) at two or more noncontiguous extrainguinal sites persisting for > 3 months in the absence of an illness other than HIV infection to account for the findings.
• AIDS related complex (ARC), defined as the presence of at least one of the following findings within 12 months prior to entry and the absence of a concurrent illness or condition other than HIV infection to explain the findings:
• Any findings which define CDC-Group IV A.
• History of any one of the findings that define CDC-Group IV C2.
• Patients with any of the ARC symptoms can also have PGL and be enrolled in the protocol as ARC patients.
• A positive antibody to HIV by any federally licensed ELISA test kit within 30 days of entry.

Concurrent Medication: Allowed:

• Topical or oral antifungal, antiviral, or antibiotic agents to treat oral candidiasis, herpes simplex, herpes zoster, or bacterial infections that develop during the course of the study.

Exclusion Criteria

• Exclude hemophiliacs.
• Active substance abuse.
• Alcohol consumption should be kept to a minimum.

Co-existing Condition:

Patients with the following will be excluded:

• Hemophilia.
• History or presence of an AIDS-defining opportunistic infection or malignancy.
• AIDS related complex (ARC) patients with prior (within the last 12 months) or current history of diarrhea defined as = or > 3 liquid stools per day persisting for longer than 1 month.
• Significant malabsorption:
• Greater than 10 percent weight loss within past 3 months with serum carotene < 75 IU/ml or vitamin A < 75 IU/ml.
• Significant cardiac, liver, renal, or neurologic disorder.
• Active ARC-defining secondary infection (oral candidiasis, oral hairy leukoplakia, multidermatomal herpes zoster, recurrent nontyphoidal Salmonella bacteremia or Nocardiosis) undergoing therapy or prophylaxis within 7 days of study entry.
• Active tuberculosis under treatment.
• Concurrent neoplasm other than basal cell carcinoma of the skin or in situ carcinoma of the cervix.

Concurrent Medication:

Excluded:

• Any medication that will interfere with the assessment of AL-721, including nutritional supplements, vitamins, laxatives, and over-the-counter products containing lecithin.
• Chemoprophylaxis for Pneumocystis carinii (PCP), candida, herpes simplex, herpes zoster infections, or bacterial infections.
• Intravenous topical or oral antifungal, antiviral, or antibiotic agents to treat oral candidiasis, herpes simplex, herpes zoster, or bacterial infections that develop during the course of the study.
• Systemic chemotherapy.

Prior Medication:

Excluded within 30 days of study entry:

• Any investigational drug.
• Biologic response modifiers.
• Corticosteroids.
• Chemotherapeutic agents.
• Excluded within 90 days of study entry:
• Any antiretroviral agent or AL-721.